These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 2664296

  • 21. Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections.
    Terheggen PM, Floot BG, Scherer E, Begg AC, Fichtinger-Schepman AM, den Engelse L.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6719-25. PubMed ID: 3315190
    [Abstract] [Full Text] [Related]

  • 22. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
    Kim WK, Kwon YE.
    Cancer Chemother Pharmacol; 2007 Jul 15; 60(2):237-43. PubMed ID: 17089165
    [Abstract] [Full Text] [Related]

  • 23. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.
    Joss RA, Kaplan S, Goldhirsch A, Sessa C, Brunner KW, Cavalli F.
    Invest New Drugs; 1984 Jul 15; 2(3):297-304. PubMed ID: 6392147
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats.
    Láznícková A, Láznícek M, Kvĕtina J, Drobník J.
    Cancer Chemother Pharmacol; 1986 Jul 15; 17(2):133-6. PubMed ID: 3521926
    [Abstract] [Full Text] [Related]

  • 25. A comparison in rodents of renal and intestinal toxicity of cisplatin and a new water-soluble antitumor platinum complex: N-methyl-iminodiacetato-diaminocyclohexane platinum (II).
    Newman RA, Khokhar AR, Sunderland BA, Travis EL, Bulger RE.
    Toxicol Appl Pharmacol; 1986 Jul 15; 84(3):454-63. PubMed ID: 3726868
    [Abstract] [Full Text] [Related]

  • 26. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
    Boughattas NA, Hecquet B, Fournier C, Bruguerolle B, Trabelsi H, Bouzouita K, Omrane B, Lévi F.
    Biopharm Drug Dispos; 1994 Dec 15; 15(9):761-73. PubMed ID: 7888604
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of mouse lip mucosa reactions after combinations of cis-diammine-1,1-cyclobutanedicarboxylate platinum (II) (CBDCA) and irradiation: single and fractionated treatments.
    Landuyt W, Keizer J, Chin A, van der Schueren E.
    Int J Radiat Oncol Biol Phys; 1987 Sep 15; 13(9):1367-70. PubMed ID: 3305448
    [Abstract] [Full Text] [Related]

  • 28. Platinum complex-induced dysfunction of cultured renal proximal tubule cells. A comparative study of carboplatin and transplatin with cisplatin.
    Courjault F, Leroy D, Coquery L, Toutain H.
    Arch Toxicol; 1993 Sep 15; 67(5):338-46. PubMed ID: 8396390
    [Abstract] [Full Text] [Related]

  • 29. In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat.
    Smith MA, Smith JH, Litterst CL, Copley MP, Uozumi J, Boyd MR.
    Fundam Appl Toxicol; 1988 Jan 15; 10(1):62-72. PubMed ID: 3350230
    [Abstract] [Full Text] [Related]

  • 30. A comparison of the effects of cisplatin and N-methyliminodiacetato-(1,2-diaminocyclohexane)-platinum(II) on renal function and gentamicin excretion in rats.
    Engineer MS, Ho DH, Khokhar AR, Newman RA, Bulger RE.
    Toxicology; 1987 Dec 14; 47(3):307-15. PubMed ID: 3424386
    [Abstract] [Full Text] [Related]

  • 31. [Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA) in humans].
    Zucca E, Cattaneo MT, Cavalli F, Guaitani A, Filipazzi V, Bartosek I.
    G Ital Chemioter; 1985 Dec 14; 32(1):25-8. PubMed ID: 3913618
    [No Abstract] [Full Text] [Related]

  • 32. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.
    Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR.
    Cancer Chemother Pharmacol; 1982 Dec 14; 9(3):140-7. PubMed ID: 6761010
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.
    Dedon PC, Borch RF.
    Biochem Pharmacol; 1987 Jun 15; 36(12):1955-64. PubMed ID: 2954556
    [Abstract] [Full Text] [Related]

  • 35. Time course of the change and amelioration of nedaplatin-induced nephrotoxicity in rats.
    Uehara T, Tsuchiya N, Masuda A, Torii M, Nakamura M, Yamate J, Maruyama T.
    J Appl Toxicol; 2008 Apr 15; 28(3):388-98. PubMed ID: 17685399
    [Abstract] [Full Text] [Related]

  • 36. Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats.
    Saad SY, Al-Rikabi AC.
    Chemotherapy; 2002 Mar 15; 48(1):42-8. PubMed ID: 11901256
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Vestibular morphological analysis of the effects of cisplatin vs. platinum analogs, CBDCA (JM-8) and CHIP (JM-9).
    Schweitzer VG, Rarey KE, Dolan DF, Abrams GE, Sheridan C.
    Laryngoscope; 1986 Sep 15; 96(9 Pt 1):959-74. PubMed ID: 3528727
    [Abstract] [Full Text] [Related]

  • 39. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
    de Jong WH, Steerenberg PA, Vos JG, Bulten EJ, Verbeek F, Kruizinga W, Ruitenberg EJ.
    Cancer Res; 1983 Oct 15; 43(10):4927-34. PubMed ID: 6683993
    [Abstract] [Full Text] [Related]

  • 40. Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study.
    Hannemann J, Baumann K.
    Arch Toxicol; 1990 Oct 15; 64(5):393-400. PubMed ID: 2169720
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.